Phaseline

Companies › Biocad

Biocad: clinical trials, targets and expected readouts

18 active drug programs in 27 registered trials: 15 Phase 3, 7 Phase 1, 5 Phase 2; Immunology, Oncology, Neurology, Hematology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nivolumab (BCD-263)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Advanced MelanomaJan 2027
nurulimab–Phase 3Melanoma; Melanoma Stage IIIJan 2027
divozilimab
anti-CD20 monoclonal antibody
MS4A1Phase 3Neuromyelitis Optica Spectrum Disorders; Systemic SclerodermaFeb 2027
ANB-002 (arvenacogene sanparvovec)
Adeno-associated viral vector carrying the FIX gene
F9Phase 3Hemophilia BApr 2027
BCD-180
anti-TRBV9 monoclonal antibody
TRBV9Phase 3Axial SpondyloarthritisJun 2027
BCD-131 (pegdarbepoetin beta)
Erythropoietin receptor (EPOR) agonist; pegylated darbepoetin beta
EPORPhase 3AnemiaOct 2027
Levilimab
Interleukin-6 receptor alpha subunit inhibitor
IL6RPhase 3Rheumatoid ArthritisDec 2027
Netakimab
IL-17A inhibitor monoclonal antibody
IL17APhase 3Plaque PsoriasisFeb 2028
BCD-248
anti-BCMA antibody-based therapy
–Phase 3Myeloma Multiple; Relapsed/Refractory Multiple MyelomaJul 2028
BCD-281
anti-CD20 monoclonal antibody
CD20Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)Dec 2028
Pertuzumab (BCD-178)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Breast Cancer–
prolgolimab
anti-PD-L1 monoclonal antibody
CD274Phase 3Melanoma–
BCD-261
Anti-TL1A human monoclonal antibody
TNFSF15, TL1APhase 2Ulcerative Colitis (UC); Crohn's Disease (CD); HealthyJan 2027
BCD-236–Phase 2Triple Negative Breast CancerMay 2027
ANB-004
Adeno-associated viral vector carrying the SMN gene
SMN1Phase 1Spinal Muscular Atrophy (SMA)Aug 2030
ANB-010
Adeno-associated viral vector carrying the FVIII gene
F8Phase 1Hemophilia AJun 2033
Litifilimab (BCD-256)
C-type lectin domain family 4 member C inhibitor
CLEC4CPhase 1Systemic Lupus Erthematosus–
Rituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 1Systemic Lupus Erthematosus–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05732805nurulimabPhase 3MelanomaOncologyJun 2024
NCT05732805prolgolimabPhase 3MelanomaOncologyJun 2024
NCT05730699divozilimabPhase 3Neuromyelitis Optica Spectrum DisordersNeurologyJan 2025
NCT06715540BCD-261Phase 1HealthyImmunologyFeb 2025
NCT05802225Pertuzumab (BCD-178)Phase 3Breast CancerOncologyJun 2025
NCT07136389Litifilimab (BCD-256)Phase 1Systemic Lupus ErthematosusImmunologyJan 2026
NCT07136389RituximabPhase 1Systemic Lupus ErthematosusImmunologyJan 2026
NCT07080034BCD-261Phase 2Ulcerative Colitis (UC)ImmunologyJan 2027
NCT06112808Nivolumab (BCD-263)Phase 1Advanced MelanomaOncologyJan 2027
NCT05751928nurulimabPhase 3Melanoma Stage IIIOncologyJan 2027
NCT05751928nurulimabPhase 3Melanoma Stage IIIOncologyJan 2027
NCT05726630divozilimabPhase 3Systemic SclerodermaImmunologyFeb 2027
NCT06640530Nivolumab (BCD-263)Phase 3Advanced MelanomaOncologyMar 2027
NCT06700096ANB-002 (arvenacogene sanparvovec)Phase 3Hemophilia BHematologyApr 2027
NCT07078994BCD-261Phase 2Crohn's Disease (CD)ImmunologyMay 2027
NCT07108309BCD-236Phase 2Triple Negative Breast CancerOncologyMay 2027
NCT05445076BCD-180Phase 2Axial SpondyloarthritisImmunologyJun 2027
NCT07119372BCD-131 (pegdarbepoetin beta)Phase 3AnemiaGenitourinaryOct 2027
NCT05800327LevilimabPhase 3Rheumatoid ArthritisImmunologyDec 2027
NCT06640517NetakimabPhase 3Plaque PsoriasisImmunologyFeb 2028
NCT06333210BCD-180Phase 3Axial SpondyloarthritisImmunologyFeb 2028
NCT07742215BCD-248Phase 3Myeloma MultipleOncologyJul 2028
NCT06668792BCD-248Phase 2Relapsed/Refractory Multiple MyelomaOncologyJul 2028
NCT07321093BCD-281Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)NeurologyDec 2028
NCT06120582ANB-002 (arvenacogene sanparvovec)Phase 1Hemophilia BHematologyNov 2029
NCT05747261ANB-004Phase 1Spinal Muscular Atrophy (SMA)NeurologyAug 2030
NCT06185335ANB-010Phase 1Hemophilia AHematologyJun 2033

Targets

MS4A1 (2) TNFSF15 (1) TL1A (1) PDCD1 (1) IL6R (1) CD274 (1) IL17A (1) SMN1 (1) CLEC4C (1) CD20 (1) TRBV9 (1) F9 (1)

Companies with the same targets

Roche AstraZeneca Akeso Shanghai Henlius Biotech Innovent Biologics (Suzhou) Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Amgen Sichuan Baili Pharmaceutical Pfizer

Companies built like this

Celltrion Sinocelltech Taizhou Mabtech Pharmaceutical Beijing VDJBio R-Pharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.